Literature DB >> 35975264

STOP-BANG QUESTIONNAIRE - AN EASY TOOL FOR IDENTIFYING OBSTRUCTIVE SLEEP APNEA SYNDROME IN PATIENTS WITH TYPE 2 DIABETES MELLITUS.

D C Protasiewicz Timofticiuc1,2, I M Vladu2,3, A G Stefan4, M C Forțofoiu5,6, A Mitrea3,7, M Fortofoiu8,9, M Mota1.   

Abstract

Background: Patients with type 2 diabetes mellitus (T2DM) have a higher risk of developing obstructive sleep apnea (OSA) compared to the general population. Our study aims to analyze the usefulness of the STOP-BANG score, tool which was not yet validated in patients with diabetets, as a tool that estimates the severity of OSA, in patients with T2DM.
Methods: 120 patients, who answered the STOP-BANG questionnaire and underwent polysomnography, were included in the study. The patients were divided into 3 groups, depending on the severity of OSA, defined by the apnea/hypopnea index (AHI).
Results: A significant percentage of participants (42.1%) had a severe form of OSA (AHI ≥30) and a high percentage of subjects had a STOP-BANG score ≥5 (58.7%), equivalent to a severe form of the disease. The STOP-BANG score increased proportionally with AHI (p<0.001). The area under the ROC curve for the STOP-Bang score indicated an optimal cut-off value of 4.5, with a sensitivity of 88.2% and a specificity of 62.9% (p <0.001), STOP-BANG score ≥5 being an independent predictor for severe OSA in patients with T2DM. Conclusions: The STOP-BANG score can be used in patients with diabetes to detect severe OSA in order to establish appropriate therapeutic measures. ©2021 Acta Endocrinologica (Buc).

Entities:  

Keywords:  STOP-BANG score; obstructive sleep apnea; polysomnography; type 2 diabetes mellitus

Year:  2022        PMID: 35975264      PMCID: PMC9365405          DOI: 10.4183/aeb.2022.49

Source DB:  PubMed          Journal:  Acta Endocrinol (Buchar)        ISSN: 1841-0987            Impact factor:   1.104


  25 in total

Review 1.  Obesity, obstructive sleep apnoea and metabolic syndrome.

Authors:  Jamie Chung Mei Lam; Judith Choi Wo Mak; Mary Sau Man Ip
Journal:  Respirology       Date:  2012-02       Impact factor: 6.424

2.  The STOP-Bang Test Is Useful for Predicting the Severity of Obstructive Sleep Apnea.

Authors:  Hideto Oshita; Noriaki Ito; Misato Senoo; Kunihiko Funaishi; Yasuyuki Mitama; Ken Okusaki
Journal:  JMA J       Date:  2020-10-02

3.  Screening for obstructive sleep apnea syndrome in patients with type 2 diabetes mellitus: a prospective study on sensitivity of Berlin and STOP-Bang questionnaires.

Authors:  Katerina Westlake; Andrea Plihalova; Martin Pretl; Zuzana Lattova; Jan Polak
Journal:  Sleep Med       Date:  2016-08-24       Impact factor: 3.492

4.  CARDIOVASCULAR RISK ASSESSMENT IN THE ADULT (AGED 40-79 YEARS) ROMANIAN POPULATION.

Authors:  M M Rosu; S G Popa; E Mota; A Popa; M Manolache; C Guja; C Bala; C Mota; M Mota
Journal:  Acta Endocrinol (Buchar)       Date:  2018 Apr-Jun       Impact factor: 0.877

5.  The utility of three screening questionnaires for obstructive sleep apnea in a sleep clinic setting.

Authors:  Bomi Kim; Eun Mi Lee; Yoo-Sam Chung; Woo-Sung Kim; Sang-Ahm Lee
Journal:  Yonsei Med J       Date:  2015-05       Impact factor: 2.759

6.  STOP-Bang questionnaire screening for obstructive sleep apnea among Chinese patients with type 2 diabetes mellitus.

Authors:  Yunjie Teng; Shuxia Wang; Ning Wang
Journal:  Arch Med Sci       Date:  2018-03-02       Impact factor: 3.318

7.  Insulin resistance quantified by the value of HOMA-IR and cardiovascular risk in patients with type 2 diabetes.

Authors:  Ionela Mihaela Vladu; Maria Forțofoiu; Diana Clenciu; Mircea-Cătălin Forțofoiu; Rodica Pădureanu; Lucrețiu Radu; Ștefăniță Tiberiu Țenea Cojan; Patricia Mihaela Rădulescu; Vlad Pădureanu
Journal:  Exp Ther Med       Date:  2021-11-24       Impact factor: 2.447

8.  A Population-Based Study of the Bidirectional Association Between Obstructive Sleep Apnea and Type 2 Diabetes in Three Prospective U.S. Cohorts.

Authors:  Tianyi Huang; Brian M Lin; Meir J Stampfer; Shelley S Tworoger; Frank B Hu; Susan Redline
Journal:  Diabetes Care       Date:  2018-08-02       Impact factor: 17.152

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.